60Dr. Janet Chollet has built a steady and enduring career shaped by clinical practice, translational research, and therapeutic development. As a board-certified obstetrician–gynecologist and co-founder of Procyrn LLC, she leads programs focused on sustained-release biologics and reformulated antivirals that address persistent needs in maternal–fetal health, neuroinflammation, and HPV-associated cervical disease. Her work is rooted in practical problem-solving and an ongoing effort to bring scientifically sound treatments closer to real clinical use.
With more than thirty years in academic and clinical medicine, she has contributed to women’s health through service at institutions such as Beth Israel Deaconess Medical Center and the University of Pittsburgh. Over the course of her career, she has earned three U.S. patents in drug-delivery innovation and supported the development of several early-stage therapeutic programs. Her efforts reinforce the value of linking clinical insight with research strategies that can feasibly progress into patient care.
Her academic path began with a Bachelor of Science in Neuroscience from the University of California, Santa Barbara, followed by a medical degree from New York Medical College. She completed her residency in Obstetrics and Gynecology at LAC/USC Women’s Hospital, where an intensive training environment strengthened her long-term interest in improving therapies for women, children, and families.
After residency, she joined Magee-Women’s Hospital as a staff physician and instructor, balancing direct patient care with clinical teaching responsibilities. She later continued her clinical work at Beth Israel Deaconess Medical Center, while expanding her role in translational research and academic training. Earlier in her career, she co-founded Pear Tree Pharmaceuticals and served as Vice President of Clinical Affairs. Her contributions to topical and vaginal drug-delivery systems led to several patents and supported the company’s later merger with Dare Bioscience.
In 2023, she co-founded Procyrn LLC, where she directs clinical development and regulatory strategy across programs addressing hypertensive disorders of pregnancy, immune-modulating approaches for ALS, and selective treatments for HPV-driven dysplasia. She also evaluates exploratory concepts related to maternal–fetal immune stabilization and the potential long-term neurodevelopmental impact. Her leadership emphasizes disciplined planning, reproducibility in preclinical work, and clear development milestones.
Her professional path has also included creative work, such as co-writing an Emmy-winning television episode early in her career. Outside of medicine, she values family, wellness, travel, and creative expression, and continues to explore how emerging technologies can support clinical workflows. Dr. Janet Chollet remains committed to advancing therapeutics that translate scientific understanding into meaningful improvements in patient care.